By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 13, 2025, that its combination therapy of SHR-A2102 for injection and Adberelimab injection has received clinical trial approval from China’s National Medical Products Administration (NMPA).
Clinical Trial Details
The combination therapy will undergo a multi-center, open-label Phase Ib/II study. The trial will investigate the efficacy and safety of SHR-A2102 and Adberelimab, with or without other anti-tumor treatments, in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Drug Profiles
- SHR-A2102: A proprietary antibody-drug conjugate (ADC) targeting Nectin-4, with a payload of topoisomerase I inhibitor (TOP1i).
- Adberelimab: A humanized anti-PD-L1 monoclonal antibody that reactivates the immune system’s anti-tumor activity by blocking the PD-1/PD-L1 pathway.-Fineline Info & Tech